Introduction: Therapeutic advances over the past 30 years have led to longer life expec-
concentrates in the 1980s and now to new agents with extended duration of action that have the potential to significantly reduce the burden of treatment for patients and carers. While innovation in therapy has the potential to greatly improve the clinical experience of patients and their families, the benefit of such impact may not be fully appreciated by other stakeholders when they lack the tools for proper assessment of efficacy. It is important for the hemophilia community as one-patients, providers and payers-to share a common interpretation of value when considering and comparing different aspects of healthcare in hemophilia.
Prophylaxis with factor concentrates is considered the current gold standard in treatment, yet has shown variable uptake both within and across different countries. There is a lack of consensus on optimal dose and regimen, age for initiating treatment, or duration of treatment, and the need for individualizing protocols adds an additional layer of complexity to this treatment modality.
Primary prophylaxis (regular, continuous treatment) is considered the most effective regime in reducing bleeding rates and preventing target joints, 2, 3, 4 whereas secondary prophylaxis (initiated after two or more bleeds into large joints) is still effective in reducing the burden of bleeding and delaying progression of arthropathy, even after irreversible damage has occurred. 5, 6 In contrast to prophylaxis, on-demand or episodic treatment refers to administration of replacement factor only in response to clinically evident bleeding.
Higher costs associated with increased usage of replacement factor products raises the question of value for either form of prophylaxis, despite evidence from several randomized controlled trials and high-quality observational studies that support its superiority over on-demand treatment. This has also been demonstrated in multiple clinically and patient-relevant outcomes, including reduced bleeding, joint damage, health resource utilization and pain, while increasing quality of life and school/work performance.
To provide a formal assessment of value of prophylaxis in hemophilia care, here we apply the outcomes hierarchy from the hemophilia value framework to expand upon our initial evaluation of prophylaxis vs on-demand therapy, conducting an evidence-based analysis using published literature from clinical trials and observational studies.
| ME THODS
To discuss and refine key points and comparators of prophylaxis vs on-demand therapy, an 8-member team consisting of experts in health economics and outcomes research, hemophilia healthcare, and patient advocacy convened in several working group meetings, both in-person and via teleconferences, to determine the outcome measures to be used in our value framework exercise. In addition, we drew on work by O'Mahony et al, who described the development of a value framework in hemophilia that is broadly applicable to several clinically relevant scenarios (O'Mahony et al, submitted).
In their paper, a framework was created to prioritize patients' health outcomes against a background of budgetary constraint as a means 
| RE SULTS

| Literature review for published trials of prophylaxis vs on-demand therapy
Six randomized clinical trials (RCTs) comparing prophylaxis vs ondemand therapy were identified: 2 evaluating primary prophylaxis, 2,3 and four evaluating secondary prophylaxis (Table 1) . 6, [8] [9] [10] Four non-controlled or observational studies were also included to supplement data on outcome measures not captured in the RCTs. [11] [12] [13] [14] To be included in the analysis, studies were required to have an on-demand comparator arm and distinction between primary and secondary prophylaxis.
The two primary prophylaxis RCTs were ESPRIT, which evaluated 45 children ages 1-7 years with severe hemophilia A (defined as trough FVIII <1%), and the Joint Outcomes Study, which evaluated 65 children aged <30 months with severe hemophilia A (defined as trough FVIII ≤2 IU/dL). 2, 3 Both compared the effects of primary prophylaxis vs on-demand therapy on bleeding rate and joint damage in children who had not yet developed a target joint. 4 Secondary prophylaxis RCTs included SPINART, LEOPOLD II, POTTER and ADVATE trials. The patient population in each study ranged from ~60 to 90 patients, ages 7-65, all with severe hemophilia A (defined as trough FVIII <1% or <1 IU/dL or ≤2%). The primary endpoint for all four studies was bleeding rate. 6, [8] [9] [10] The four non-controlled or observational only studies included a survey of 124 men ages 18-35 years with severe hemophilia A or B, the longitudinal, 6-year, Orthopaedic Outcome Study of 673 patients <25 years with severe hemophilia, and a cross-sectional investigation of academic achievement in 131 patients with severe hemophilia, ages 6-12 years. 11, 12, 14 The fourth study was a nested case-control study that evaluated association of prophylaxis with intracranial hemorrhage (ICH), using the CDC Universal Data Collection project database of 10 262 persons ≥2 years with hemophilia A or B.
13 prophylaxis was associated with significantly fewer annual joint and total hemorrhages in the Joint Outcomes Study (JOS), fewer hemarthroses events in the ESPRIT study, and lower annual bleeding rates (ABR) in both. 2, 3 In studies of secondary prophylaxis, significantly fewer bleeding episodes occurred with prophylaxis than on-demand in both the SPINART and POTTER studies, 6, 8 and higher proportions of patients were bleed-free during the ADVATE study. 10 Serious and life-threatening bleeds and musculoskeletal complications (ie, development of target joints, joint deterioration) were also experienced by fewer patients on prophylaxis than on-demand therapy. 2, 3, [8] [9] [10] In the Tier 1 outcome measure of HRQOL, self-reported scores were higher among adolescents on prophylaxis in the dimension of "family." 3 Children receiving on-demand treatment reported feeling overprotected and having time at work or leisure limited by their parents due to their hemophilia. 3, 6 Cure was deemed not applicable for comparisons of prophylaxis and on-demand therapy, given that neither is currently considered curative therapy.
| Tier 2: process of recovery
Tier 2 of the value framework refers to process of recovery and includes measures in two categories of time to recovery/return to normal activities and disutility of care or treatment process. While time to initial diagnosis was not considered relevant to this analysis, both primary and secondary prophylaxis reduced the number of lost days of work or school, as well as improved perception of having limitations to leisure or daily activities. 3, 6, 11, 14 Sparse data were available on time to recovery from bleeding episodes, although the nature of each mode of treatment should theoretically favour prophylaxis, given the increase in trough levels of clotting factor. Likewise, data on time to onset of treatment were limited to clinical trial design, with prophylaxis entailing regular continuous treatment, whereas on-demand therapy is given at time of clinically evident bleeding; primary or secondary prophylaxis are initiated either prior to or after two bleeds, respectively.
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In the second category of Tier 2, disutility of care or treatment process, more data were available from primary prophylaxis than secondary prophylaxis trials. Primary prophylaxis was associated with fewer surgeries or other invasive procedures, 14 but slightly increased use of indwelling catheters and associated infections in the ESPRIT study. 3 Secondary prophylaxis was also associated with fewer jointrelated surgeries, 16 but no head-to-head comparisons were made for infections or catheter use. Results on inhibitors are difficult to interpret, as all of the RCTs and most of the non-controlled and observational studies excluded patients with inhibitors. on-demand therapy. [8] [9] [10] 14 Joint preservation was noted in primary prophylaxis studies, 2,3 but not with secondary prophylaxis. 19 Longterm productivity was improved with prophylaxis, as measured by academic achievement in children receiving primary prophylaxis 12 and intensity of physical or recreational activities and school or work in adolescents or adults receiving secondary prophylaxis. 20 Long-term consequences of therapy, such as long-term disutility of insufficient or inappropriate therapy and age-related comorbidities and complications, were not measured in clinical trials.
| Tier 3: sustainability of health
| D ISCUSS I ON
Progress in hemophilia treatment has led to significant gains in survival, from median life expectancies of ~8-11 years in the early 1900s to 75+ years now, which is approaching that of the general male population. 23 This is even more remarkable considering some major setbacks, most notably the contamination of donor plasma with HIV and hepatitis viruses, which led to high infection and mortality rates in recipients of pooled plasma products from the 1970s to 1990s. The traumatic experience of plasma-borne infection changed the focus from efficacy to safety of therapy, and led to the development of plasma-free recombinant factor concentrates. In the three decades since this tragedy, scientific and technological advances have now led to safe and innovative therapy with real potential to improve the clinical experience and outcomes for those with hemophilia.
Along with the changing landscape of hemophilia healthcare, quality of life and ability to lead a normal life have become priorities for patient care. In addition, increased life expectancy has led to a growing need for management of previously unseen comorbidities associated with ageing. Evaluation of treatments and other areas of hemophilia comprehensive care cannot be limited to singular efficacy or safety measures, but must also incorporate a multitude of both direct and indirect effects of treatment. Porter supports this notion, highlighting that patient-centred outcomes "encompass the whole cycle of care," including both clinical status and functional outcomes, as described in this paper. 25 Assessment of value must take into consideration the trade-offs in selecting a particular treatment modality over another, eg, the balance of survival gains or improvements in bleed rates and joint damage on the one hand, vs safety concerns and incremental costs of treatment on the other hand. • Number of patients with joint damage: 6 (29%) vs 14 (74%; P < 0.05) 3
Health-related quality of life (physical, mental, emotional, social functionality score)
• Haemo-QOL score was good overall, as assessed by both the patients and their parents • Significantly better mean score in dimension of family with prophylaxis: 11.27 (±8.7) vs 44.0 (±22.6; P < 0.29) • Prophylaxis entails regular continuous treatment, whereas on demand treatment is given at time of clinically evident bleeding. Primary prophylaxis is administered prior to the second clinically evident large joint bleed and age 3 y
Secondary prophylaxis vs on-demand
Ref.
No head-to-head comparisons
No head-to-head comparisons
• Prophylaxis significantly associated with fewer lost days of everyday activities (P < 0.0001) 6
• Median number of total bleeding episodes: 0 vs 54. • Reduced rate of joint deterioration on physical and X-ray examination (P = 0.02 and <0.001, respectively) 11
• Prophylaxis arm reported better HRQOL than those treated on demand in SF-36 domains of physical functioning, role physical, social functioning and role emotional; EQ-5D visual analogue scale; and Haemo-QOL-A domains of physical functioning, roe functioning, worry, consequence of bleeding and total score (P < 0.05 for all) 6
• Significant improvement in Physical Component Score of SF-36 in prophylaxis arms of study (P = 0.0007) 10 NA NA
• Prophylaxis entails regular continuous treatment, whereas on demand treatment is given at time of clinically evident bleeding. Secondary prophylaxis is initiated after 2 or more bleeds into large joints and prior to onset of joint disease
(Continues)
Primary prophylaxis vs on-demand Ref.
Time to recover from a bleeding episode (time to stop bleeding, recurrence of a bleed in the same location)
• No head-to-head comparison Time missed at education or employment for treatment (for patients or caregivers, including the ability to save for retirement, have financial security)
• Perception that time at work or leisure was "often" or "always" disrupted for parents due to hemophilia: 0% vs 20% Lifelong productivity (ability to maintain productivity, learn, work and contribute to society over time)
• Children on long-term prophylaxis (>40% of lifetime) and with successful bleeding control had significantly higher scores in total achievement, math and reading, compared with all other children with ≥12 bleeding episodes
12
Sustained good health (high HRQOL and health utility over time)
• After a mean ~82-mo follow-up, Haemo-QOL score was good overall, as assessed by both the patients and their parents • Significantly better mean score in dimension of family with prophylaxis: 11.27 (±8.7) vs 44.0 (±22.6; P < 0.29)
3
Long-term consequences of therapy (eg, care-induced illnesses)
Long-term disutility of insufficient or inappropriate therapy
• No head-to-head comparison Age-related comorbidities and complications (due to increased life expectancy)
• No head-to-head comparison ABR, annual bleeding rate; NA, not applicable; n.s., not significant; SF-MPQ, short form McGill Pain Questionnaire. a In the CDC/UDC Study, prophylaxis was associated with significant risk reduction for intracranial hemorrhage (a leading cause of death) in patients with severe hemophilia who were negative for HIV or an inhibitor. Patients were not stratified by primary vs secondary prophylaxis, although the majority of patients prescribed prophylaxis (79.2%) were <20 y of age. b Comparison of survey participants in the "always prophylaxis" group vs the "always on-demand group". c Minimal important difference for SF-36 instrument used is estimated at 3 points. d Ten of 20 patients on prophylaxis required indwelling catheters, compared to none in the episodic therapy group. e Inconvenience of frequent venipunctures has been cited as a reason why some patients quit prophylaxis in adolescence or adulthood; use of central venous access devices has been associated with risk of sepsis and thrombosis. 21, 22 Ta b l e 2 . (Continued)
Secondary prophylaxis vs on-demand Ref.
• Proportion of bleeds per patient successfully treated with ≤2 injections: 100% vs 97%
• Prophylaxis was associated with significantly fewer days lost from work or school 11
• Prophylaxis is widely accepted as the standard and ideal treatment of hemophilia worldwide, but replacement factor usage for prophylaxis is considered cost-prohibitive for some regions of the world.
Estimations of cost-utility for hemophilia care have been variable for several reasons. When evaluating the cost-utility of prophylaxis vs on-demand therapy, use of many different instruments has led to large variations in estimates, with no clarity as to which instruments are most useful. 26 Furthermore, selection bias due to increased prophylaxis use in individuals who have more bleeding events due to later initiation of prophylaxis and other comorbidities could potentially lead to an inverse association of prophylaxis with health scores. 27 Establishing value concepts and practical frameworks pose challenges, including identification of well-defined parameters, such as outcome measures, determination of cost, and adjustment for biases or confounding factors, different life stages, and societal priorities. 28 Other factors include robustness of collected data, implementation of decisions and impact on innovation (ie, appropriate valuation of new therapies and risk of impeding progress). 28, 29 To address challenges for establishing value of prophylaxis, we . 23 The aim of prophylaxis is to increase and maintain trough levels of clotting factor above the threshold used for defining severe hemophilia, ultimately changing the severity classification from se- who receive prophylaxis (OR = 0.5; P < 0.01). 13 Tier 3 outcomes that measure disutility of insufficient therapy-and age-related complications have not been published to date, likely due to the growing but currently small population of ageing persons with hemophilia and the lack of RCTs evaluating these endpoints. With advancement of age and increased reporting in clinical databases, we anticipate future data that can be meaningfully applied to the value framework.
| CON CLUS ION
This evidence-based analysis demonstrated successful application of 3-tiered hemophilia value framework to an assessment of value of prophylaxis, both primary and secondary, as compared to on-demand therapy. In addition to highlighting the importance of clinical research to support interpretation of value, this effective tool enables providers, patients and payers to assess the comparative value of new treatment modalities and gives all parties a transparent process with common language to assess outcomes, ease and effectiveness of treatment and cost-effectiveness of each therapeutic approach. It is important to note that use of the value framework serves to complement clinical research, but does not seek to replace it. Finally, the value framework is an excellent process for assisting stakeholders in decision-making that is grounded in patient-centred value.
ACK N OWLED G EM ENTS
All authors contributed to the analysis, interpretation of findings and writing of the manuscript. Ingrid Koo, Ph.D., a contract medical writer funded by Bayer, provided writing support during manuscript development. 
D I SCLOS U R E S
